Haywood Regional Medical Center Offering Monoclonal Antibody Treatment for COVID-19 Patients

February 26, 2021

Haywood Regional Medical Center (HRMC) announced that it is offering bamlanivimab and casirivimab/imdevimab, new monoclonal antibody therapies, for treatment of non-hospitalized patients with a mild or moderate case of COVID-19. Developed by pharmaceutical company Eli Lilly and Regeneron Pharmaceuticals, Inc., respectively, the drug recently received emergency use authorization (EUA) from the Food and Drug Administration (FDA) and is now being allocated by the U.S. Department of Health and Human Services (HHS) in partnership with the NCDHHS and other state agencies.

Monoclonal antibodies are laboratory-made proteins that mimic the immune system’s ability to fight off harmful viruses. Bamlanivimab and casirivimab/imdevimab are specifically designed to help block the SARS-CoV-2 virus and prevent the virus from further infecting healthy cells. Administered intravenously, these innovative treatments are designed to help lessen the severity of COVID-19 in individuals who are COVID-19-positive and are at risk for developing a severe form of the disease.

“Haywood is proud to offer this treatment locally for qualifying patients, and our team has seen promising results in our initial patients,” said Susan Mahoney, CNO at HRMC. “Offering this treatment locally is an important step forward in helping prevent the most at-risk patients from being hospitalized due to COVID-19.”

Patients must meet specific clinical criteria, including having a lab-confirmed case of COVID-19 that is mild or moderate; having underlying health conditions or > 65 years of age; and being stable enough not to require hospitalization. As bamlanivimab and casirivimab/imdevimab are investigational treatments, the hospital’s supply is limited and carefully allocated by NCDHHS and requires an order from the patient’s provider.
 

FAQs:

What is bamlanivimab and casirivimab/imdevimab or monoclonal antibody treatment?
Bamlanivimab and casirivimab/imdevimab are monoclonal antibody treatments developed by pharmaceutical companies Eli Lilly and Regeneron Pharmaceuticals, to help treat non-hospitalized patients with a mild or moderate case of COVID-19 (SARS-CoV-2). Monoclonal antibodies are laboratory-made proteins that mimic the immune system's ability to fight off harmful viruses. This therapy is designed to help block the COVID-19 virus and prevent the virus from further infecting healthy cells.

Bamlanivimab and casirivimab/imdevimab have received Emergency Use Authorization (EUA) from the Food and Drug Administration (FDA) and is now being allocated by the U.S. Department of Health and Human Services (HHS), in partnership with the NCDHHS.

Who is a candidate for monoclonal antibody treatment?

Adults and adolescents 12 years of age or older, with mild to moderate symptoms, who weigh 88 pounds (40 kg) or more, and who are at high risk for developing severe COVID-19 symptoms or the need for hospitalization.

Patients must meet specific clinical criteria including:

  • Lab-confirmed COVID-19 positive test
  • Stable enough to not require hospitalization
  • Be within 10 days of symptom onset

In addition to meeting the above criteria, patients must also have an order from a provider to receive this treatment.

Who is NOT a candidate for this treatment?

This treatment will not be considered for patients who are currently hospitalized due to COVID-19, require oxygen therapy for COVID-19, and/or have a known hypersensitivity to bamlanivimab or casirivimab/imdevimab.

How does a patient qualify for this treatment?

This therapy requires an order from a healthcare provider, including specified order form and complete referral information.

Patients may:

  1. Contact their primary care physician (PCP) to make an appointment, OR
  2. Call the Provider Referral Line (PRL) at 800.424.DOCS (3627) or visit our Find a Doctor feature.

What should patients expect?

A physician’s office will provide steps on how and where patients will receive their treatment. Treatment is administered intravenously (using IV therapy). Patients receiving treatment through Haywood Regional Medical Center’s Homestead location should expect to stay for a duration of at least 2 hours.

Important facts about bamlanivimab

For information on the authorized use of bamlanivimab and mandatory requirements under the Emergency Use Authorization, please review:
Fact Sheet for Patients, Parents and Caregivers (English)
Fact Sheet for Patients, Parents and Caregivers (Spanish)

Important facts about casirivimab/imdevimab

For information on the authorized use of casirivimab/imdevimab and mandatory requirements under the Emergency Use Authorization, please review:
Fact Sheet for Patients, Parents and Caregivers (English)
Fact Sheet for Patients, Parents and Caregivers (Spanish)